TG THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.52 USD | -3.33% |
|
-3.93% | -21.31% |
| Apr. 18 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| Apr. 18 | Sector Update: Health Care | MT |
Financials (USD)
| Sales 2024 * | 268M | Sales 2025 * | 416M | Capitalization | 2.16B |
|---|---|---|---|---|---|
| Net income 2024 * | -24M | Net income 2025 * | 83M | EV / Sales 2024 * | 7.53 x |
| Net cash position 2024 * | 146M | Net cash position 2025 * | 259M | EV / Sales 2025 * | 4.57 x |
| P/E ratio 2024 * |
-83.9
x | P/E ratio 2025 * |
26.9
x | Employees | 264 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on TG Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.89% | ||
| 1 week | +1.16% | ||
| Current month | -8.09% | ||
| 1 month | -9.75% | ||
| 3 months | -10.78% | ||
| 6 months | +88.66% | ||
| Current year | -18.15% |
1 week
13.26
14.57
1 month
13.2615.99
Current year
12.8422.67
1 year
6.4635.67
3 years
3.4845.50
5 years
3.4856.74
10 years
3.3256.74
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 76 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 13.43 | -3.93% | 372 184 |
| 24-04-24 | 13.98 | -1.89% | 2,725,253 |
| 24-04-23 | 14.25 | +1.06% | 3,222,795 |
| 24-04-22 | 14.1 | +2.32% | 2,273,680 |
| 24-04-19 | 13.78 | -1.50% | 3,665,975 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.98
USD
Average target price
29.75
USD
Spread / Average Target
+112.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.15% | 2.16B | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- TGTX Stock
